Holen Sie sich die Stockscreener-App
61.03
2.42%
1.44
Handel nachbörslich:
61.90
0.87
+1.43%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - GlobeNewswire Inc.
Cytokinetics stock hits 52-week high at 61.48 USD By Investing.com - Investing.com South Africa
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cytokinetics, - GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK - GlobeNewswire Inc.
Class Action Filed Against Cytokinetics, Incorporated - GlobeNewswire
Recover Investment Losses: Class Action Initiated Against Cytokinetics, Incorporated (CYTK) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming DeadlinesCYTK - PR Newswire
Is Cytokinetics Incorporated forming a bottoming base2025 Market Overview & Capital Efficiency Focused Strategies - newser.com
Is it time to cut losses on Cytokinetics Incorporated2025 Performance Recap & High Conviction Investment Ideas - newser.com
Aberdeen Group plc Buys 320,508 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Securities Lawsuit Alert: Cytokinetics, Incorporated (CYTK)Contact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FinancialContent
Cytokinetics, Incorporated $CYTK Stake Increased by Mirae Asset Global Investments Co. Ltd. - Defense World
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI to Contact the Firm About their Rights in Filed Class Action Lawsuits - GlobeNewswire
ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, - GlobeNewswire
Shareholders of Cytokinetics, Incorporated (CYTK): Protect Your Rights Before November 17, 2025Contact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class ActionCYTK - PR Newswire
State of Alaska Department of Revenue Decreases Stake in Cytokinetics, Incorporated $CYTK - Defense World
Weiss Ratings Reiterates "Sell (D-)" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
CYTK SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - PR Newswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCYTK - Eastern Progress
Cytokinetics, Inc. Hits New 52-Week High at USD 61.42 - Markets Mojo
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated. Investors - GlobeNewswire
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
Cytokinetics, Incorporated Sued for Securities Law Violations - GuruFocus
How Cytokinetics Incorporated stock benefits from tech adoptionTreasury Yields & AI Enhanced Market Trend Forecasts - newser.com
Top chart patterns to watch in Cytokinetics IncorporatedWeekly Stock Report & Step-by-Step Swing Trade Plans - newser.com
Should I hold or sell Cytokinetics Incorporated stock in 2025July 2025 Summary & Low Drawdown Trading Strategies - newser.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo
Cytokinetics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com
Cytokinetics, Inc. Hits New 52-Week High at $61.00 - Markets Mojo
Cytokinetics Shareholder Alert By Former Louisiana Attorney - GlobeNewswire
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 2,000 Shares - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Cytokinetics, - GlobeNewswire
Malik, Cytokinetics evp, sells $121k in shares - Investing.com
Key facts: Pomerantz LLP filed a class action lawsuit against Cytokinetics on October 6-7, 2025, alleging securities fraud. Investors can apply to be Lead Plaintiff until November 17, 2025. - TradingView
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
December 19th Options Now Available For Cytokinetics (CYTK) - Nasdaq
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire
Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming - GuruFocus
Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against CYTK - PR Newswire
Insider Sell: Kaye Edward M. MD Sells 6,757 Shares of Cytokineti - GuruFocus
Lost Money on Cytokinetics, Incorporated (CYTK)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
Investors in Cytokinetics, Incorporated (CYTK): Protect Your RightsContact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
Cytokinetics (NASDAQ:CYTK) Hits New 12-Month HighShould You Buy? - MarketBeat
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit | FinancialContent - FinancialContent
Cytokinetics stock hits 52-week high at 59.5 USD - Investing.com
Cytokinetics stock hits 52-week high at 59.5 USD By Investing.com - Investing.com Australia
Barclays Raises Price Target for Cytokinetics (CYTK) to $82 | CY - GuruFocus
Class Action Filed Against Cytokinetics, Incorporated (CYTK)November 17, 2025 Deadline to JoinContact The Gross Law Firm - Morningstar
Lost Money on Cytokinetics, Incorporated (CYTK)? Contact Levi & Korsinsky Before November 17, 2025 to Join Class Action - ACCESS Newswire
Lost Money on Cytokinetics, Incorporated (CYTK)? Join Class Action Before November 17, 2025Contact Levi & Korsinsky - ACCESS Newswire
Can Cytokinetics Incorporated (KK3A) stock sustain breakout momentumEarnings Recap Report & Real-Time Volume Triggers - newser.com
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit - Eastern Progress
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, - GlobeNewswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel ... - Caledonian Record
J. Safra Sarasin Holding AG Grows Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):